Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...
Teleflex TFX banks on strong UroLift system prospects. The Vascular Solutions business has been contributing to the company’s top line quite handsomely. Yet, escalating operating expenses are putting ...
WAYNE, Pa.--(BUSINESS WIRE)--NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the publication of ...
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) presented significant clinical findings at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas. The data from two randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results